MAT, or medication-assisted treatment, is the use of FDA-approved medications combined with counseling and behavioral therapies to treat substance use disorders, primarily opioid and alcohol addiction. It’s considered a “whole-patient” approach, meaning it targets both the physical chemistry of addiction and the psychological patterns that drive it. MAT is one of the most effective treatments available for opioid use disorder, and recent federal changes have made it significantly easier to access.
How MAT Works
Addiction changes the brain’s reward system. When someone becomes dependent on opioids or alcohol, their brain chemistry shifts so that normal functioning requires the substance. Stopping abruptly causes withdrawal, and the intense cravings that follow make relapse extremely common. MAT addresses this by using medications that stabilize brain chemistry, reduce cravings, and block the euphoric effects of the addictive substance. The medications don’t produce a high at therapeutic doses. Instead, they occupy the same receptors in the brain that the addictive substance targets, either partially activating them to prevent withdrawal or blocking them entirely so the substance no longer has its rewarding effect.
The behavioral therapy side of MAT provides structure and coping skills. Common approaches include cognitive-behavioral therapy, contingency management (a reward-based system where patients earn incentives for drug-free urine tests or meeting treatment goals), and counseling focused on co-occurring issues like depression and anxiety. Research consistently shows that combining medication with these therapies produces better outcomes than either approach alone.
Medications for Opioid Use Disorder
The FDA has approved three medications for opioid use disorder: buprenorphine, methadone, and naltrexone. Each works differently, and the right choice depends on where someone is in their recovery.
Buprenorphine is a partial activator of the brain’s opioid receptors. It binds tightly to those receptors, which does two things: it provides just enough stimulation to prevent withdrawal and cravings, and it blocks other opioids from producing a high if someone relapses. Because it only partially activates the receptor, it carries a lower risk of overdose than full-strength opioids. Buprenorphine is available as dissolving tablets, films placed under the tongue or inside the cheek, and long-acting injections given monthly. Many formulations combine buprenorphine with naloxone, an opioid blocker that discourages misuse.
Methadone is a full activator of opioid receptors, but it works slowly and steadily rather than producing the rapid surge that heroin or prescription painkillers cause. It’s taken as a liquid or tablet, typically at a specialized clinic under daily supervision, at least in the early stages of treatment. Common side effects include sweating, nausea, constipation, and drowsiness. Methadone can also affect heart rhythm in some people, so it requires careful medical monitoring.
Naltrexone takes the opposite approach. Rather than activating opioid receptors, it blocks them entirely. If someone takes an opioid while on naltrexone, they won’t feel the effects. The catch is that a person must be fully detoxed before starting naltrexone. If any opioids remain in the system, naltrexone will displace them from the receptors all at once, triggering sudden and severe withdrawal. It’s given as a monthly injection for opioid use disorder.
Medications for Alcohol Use Disorder
MAT also applies to alcohol addiction, with three FDA-approved options: naltrexone, acamprosate, and disulfiram. Naltrexone works similarly for alcohol as it does for opioids, reducing the pleasurable effects of drinking and dampening cravings. Acamprosate helps restore the brain’s chemical balance after someone stops drinking, easing the prolonged discomfort that can persist for months after quitting. Disulfiram takes a deterrent approach: it causes unpleasant reactions like nausea and flushing if someone drinks alcohol while taking it.
How Effective MAT Is
Retention in methadone and buprenorphine treatment is associated with substantial reductions in the risk of death from all causes, including overdose. The numbers make the stakes clear. Over 80% of methadone patients who stop treatment return to using heroin within one year.
A large study of Medicaid enrollees found that staying on medication beyond 60 days reduced the risk of overdose by roughly 61% compared to those who stopped before that point. The protection kept growing with time: at 180 days, overdose risk dropped by about 69%, and by 300 days, it dropped by 72%. Every additional 60 days of treatment lowered the risk of overdose by another 10%. In other words, the longer someone stays on medication, the safer they are, with benefits accumulating up to at least 12 months.
There is no medical consensus on exactly how long MAT should last. Expert recommendations range from a minimum of six months with no set maximum to simply “as long as it provides a benefit.” For many people, that means years or even indefinitely, much like taking medication for diabetes or high blood pressure.
Recent Changes in Access
Getting MAT used to be harder than it needed to be. Until 2023, doctors who wanted to prescribe buprenorphine had to apply for a special federal waiver, face limits on how many patients they could treat, and meet certification requirements around counseling services. The Consolidated Appropriations Act of 2023, sometimes called the MAT Act, eliminated all of that.
Now, any practitioner with a standard DEA registration that includes authority to prescribe Schedule III medications can prescribe buprenorphine for opioid use disorder. There are no patient caps, no special waiver applications, and no separate registration numbers required on prescriptions. The only new requirement is that practitioners applying for or renewing their DEA registration must complete at least eight hours of training on substance use disorders, or hold board certification in addiction medicine, or have graduated within the past five years from a program that included substance use disorder training.
Counseling is still strongly recommended as part of treatment, but it’s no longer a federal requirement for prescribing. This change was designed to dramatically expand the number of providers who can offer buprenorphine, particularly in rural areas and primary care settings where access to specialized addiction treatment has been limited. State laws still apply, so availability varies by location.
What Treatment Looks Like Day to Day
The experience of MAT depends on which medication you’re using. Methadone treatment often starts with daily visits to a specialized clinic, where you take your dose under observation. Over time, as you stabilize, you may earn the ability to take doses home. Buprenorphine is more flexible from the start. A primary care doctor can prescribe it, and you take it at home, typically as a daily dissolving tablet or film, or as a monthly injection at a clinic. Naltrexone involves a monthly injection at a provider’s office after completing detox.
On the behavioral side, most MAT programs involve some combination of individual counseling, group therapy, or structured programs. Contingency management, where you earn small rewards for meeting goals like attending sessions or providing clean drug tests, has particularly strong evidence behind it. Some programs now incorporate brief web-based interventions, which have shown meaningful improvements in treatment retention for people on buprenorphine.
The early weeks of treatment focus on finding the right medication dose and managing any side effects. Once stabilized, many people describe feeling “normal” for the first time in years. They can work, maintain relationships, and function without the constant cycle of craving, using, and withdrawal. The medication doesn’t create euphoria. It creates a stable baseline that makes the hard work of behavioral change possible.